Clinical Trial Update: A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients [Phase 4]

View source ↗

Summary

A single-center, open-label randomized Phase 4 pilot study evaluated the safety and efficacy of tacrolimus modified-release (ADVAGRAF) versus tacrolimus twice-d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Advagraf (tacrolimus)
• Prograf (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Korea, Inc. | Conditions: Renal Transplantation, Kidney Transplantation | Phase 4 | Status: COMPLETED